Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Express Scripts
Queensland Health
Novartis
Mallinckrodt
Fish and Richardson
Cipla
Colorcon
Teva
Healthtrust

Generated: February 21, 2018

DrugPatentWatch Database Preview

VERELAN PM Drug Profile

« Back to Dashboard

When do Verelan Pm patents expire, and what generic alternatives are available?

Verelan Pm is a drug marketed by Recro Gainesville and is included in one NDA.

The generic ingredient in VERELAN PM is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

US Patents and Regulatory Information for VERELAN PM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for VERELAN PM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VERELAN PM
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 100 mg and 200 mg ➤ Subscribe 7/20/2006
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 5/19/2006

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Chubb
Julphar
McKinsey
Moodys
Fish and Richardson
Express Scripts
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot